These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28635633)

  • 1. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
    Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
    Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53-homologue p63 may promote thyroid cancer progression.
    Malaguarnera R; Mandarino A; Mazzon E; Vella V; Gangemi P; Vancheri C; Vigneri P; Aloisi A; Vigneri R; Frasca F
    Endocr Relat Cancer; 2005 Dec; 12(4):953-71. PubMed ID: 16322335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
    Preto A; Reis-Filho JS; Ricardo S; Soares P
    Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
    Manzella L; Massimino M; Stella S; Tirrò E; Pennisi MS; Martorana F; Motta G; Vitale SR; Puma A; Romano C; Di Gregorio S; Russo M; Malandrino P; Vigneri P
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
    Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A
    Oncotarget; 2011 Dec; 2(12):1109-26. PubMed ID: 22190384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
    Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
    J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
    Riesco-Eizaguirre G; Santisteban P
    Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
    Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
    J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.
    La Perle KM; Jhiang SM; Capen CC
    Am J Pathol; 2000 Aug; 157(2):671-7. PubMed ID: 10934169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to thyroid cancer.
    Cohen EE
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
    Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-targeted approach in the treatment of thyroid cancer.
    Zarebczan B; Chen H
    Minerva Chir; 2010 Feb; 65(1):59-69. PubMed ID: 20212418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors.
    Zedenius J; Larsson C; Wallin G; Bäckdahl M; Aspenblad U; Höög A; Børresen AL; Auer G
    Thyroid; 1996 Feb; 6(1):1-9. PubMed ID: 8777377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.
    Grassi ES; Vezzoli V; Negri I; Lábadi Á; Fugazzola L; Vitale G; Persani L
    Oncotarget; 2015 Nov; 6(34):36383-99. PubMed ID: 26415230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.